Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 4.5% - What's Next?

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report)'s share price fell 4.5% during mid-day trading on Thursday . The company traded as low as $21.69 and last traded at $21.70. 240,743 shares were traded during mid-day trading, a decline of 72% from the average session volume of 856,369 shares. The stock had previously closed at $22.72.

Wall Street Analyst Weigh In

A number of research firms have weighed in on GPCR. William Blair began coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. HC Wainwright decreased their target price on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research report on Monday, May 12th. Finally, Citigroup started coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $76.50.

Structure Therapeutics Trading Down 2.4%

The stock's 50-day moving average is $22.64 and its 200-day moving average is $24.62. The stock has a market cap of $1.24 billion, a P/E ratio of -29.30 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). On average, equities analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC lifted its holdings in shares of Structure Therapeutics by 5.1% during the fourth quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company's stock valued at $112,816,000 after acquiring an additional 203,010 shares during the period. Deep Track Capital LP grew its position in shares of Structure Therapeutics by 129.4% during the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock worth $75,936,000 after buying an additional 1,579,492 shares during the period. Vestal Point Capital LP grew its position in shares of Structure Therapeutics by 3.7% during the 1st quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock worth $30,967,000 after buying an additional 63,990 shares during the period. Capital International Investors grew its position in shares of Structure Therapeutics by 6.8% in the 4th quarter. Capital International Investors now owns 1,619,081 shares of the company's stock valued at $43,909,000 after purchasing an additional 103,059 shares during the period. Finally, Ameriprise Financial Inc. lifted its stake in Structure Therapeutics by 29.4% in the 4th quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock valued at $38,512,000 after acquiring an additional 322,601 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.